Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. (Q35791105)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Richard B Lock

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

C P Reynolds

series ordinal

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Min H Kang

series ordinal

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

3

Peter J Houghton

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

2

John M Maris

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

12

Malcolm A Smith

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

6

Raushan T Kurmasheva

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

7

E Anders Kolb

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

8

Stephen T Keir

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

5

Hernan Carol

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

11

Catherine A Billups

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

18 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

published in

Pediatric Blood & Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

518-524

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo

17 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Targeting the phosphoinositide 3-kinase pathway in cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

AKT/PKB signaling: navigating downstream

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Activation of Akt predicts poor outcome in neuroblastoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Insulin-like growth factor-I induces the phosphorylation and nuclear exclusion of forkhead transcription factors in human neuroblastoma cells.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Activation of AKT kinases in cancer: implications for therapeutic targeting

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

AKT/PKB signaling mechanisms in cancer and chemoresistance

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

PI3K-Akt pathway: its functions and alterations in human cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Ten years of protein kinase B signalling: a hard Akt to follow

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival

27 July 2018

1 reference

Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

21 January 2018

1 reference

Insulin-like growth factor I induces preferential degradation of insulin receptor substrate-2 through the phosphatidylinositol 3-kinase pathway in human neuroblastoma cells

21 January 2018

1 reference

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies

21 January 2018

1 reference

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability

21 January 2018

1 reference

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

21 January 2018

1 reference

The pediatric preclinical testing program: description of models and early testing results.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Resistance to chemotherapy mediated by TrkB in neuroblastomas.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3290691

Guidelines for accurate EC50/IC50 estimation

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22102563

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22102563

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/PBC.23412

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22102563%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

PubMed publication ID

22102563

1 reference